nach oben

Erschienen in:

08.08.2022 | COVID-19 | Review

Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail

verfasst von: Shadi Salem Alkhayyat, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Maisra M. El-Bouseary, Amal M. AboKamer, Gaber El-Saber Batiha, Jesus Simal-Gandara

Erschienen in: Inflammation Research | Ausgabe 10-11/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofibrate in the pathogenesis of SARS-CoV-2 and related complications.

Results

By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofibrate can reduce SARS-CoV-2 entry in human cells Fenofibrate also suppresses inflammatory signaling pathways, which decreases SARS-CoV-2 infection-related inflammatory alterations. In conclusion, fenofibrate anti-inflammatory, antioxidant, and antithrombotic capabilities may help to minimize the inflammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction between SARS-CoV-2 and ACE2, fenofibrate can directly reduce the risk of SARS-CoV-2 infection.

Conclusions

As a result, fenofibrate could be a potential treatment approach for COVID-19 control.

Rasheed HA, Hussien NR, Al-Naimi MS, Al-Kuraishy HM, Al-Gareeb AI. Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia. Biomed Biotechnol Res J. 2020;4(3):259. https://doi.org/10.4103/bbrj.bbrj_26_20.CrossRef

Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, et al. Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci USA. 2018;115(4):E743–52. https://doi.org/10.1073/pnas.1714703115.CrossRefPubMedPubMedCentral

Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. SciRep. 2018;8(1):16767. https://doi.org/10.1038/s41598-018-35175-z.CrossRef

FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.CrossRef

Fischer J, Ganellin CR. Analogue-based drug discovery. Chem Int—Newsmag IUPAC. 2010;32(4):12–5.

Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L. Rare side-effects of fenofibrate. Diabetes Metab. 2001;27(1):66–8.PubMed

Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. CurrVascPharmacol. 2005;3(1):87–98. https://doi.org/10.2174/1570161052773942.CrossRef

Sehgal N, Kumawat KL, Basu A, Ravindranath V. Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection. PLOSONE. 2012;7(4): e35427. https://doi.org/10.1371/journal.pone.0035427.CrossRef

Alleva LM, Budd AC, Clark IA. Minimising influenza disease with fibrates. Int J InfectDis. 2008;12: e176. https://doi.org/10.1016/j.ijid.2008.05.440.CrossRef

10.

Badiou S, Merle De Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004;172(2):273–9. https://doi.org/10.1016/j.atherosclerosis.2003.10.006.CrossRefPubMed

11.

Huang W, Chen L, Zhang B, Park M, Toborek M. PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. J Cereb Blood Flow Metab. 2014;34(4):646–53. https://doi.org/10.1038/jcbfm.2013.240.CrossRefPubMedPubMedCentral

12.

Huang W, Rha GB, Han MJ, Eum SY, András IE, Zhong Y, et al. PPARα and PPARγ effectively protect against HIV-induced inflammatory responses in brain endothelial cells. J Neurochem. 2008;107(2):497–509. https://doi.org/10.1111/j.1471-4159.2008.05626.x.CrossRefPubMedPubMedCentral

13.

Glitscher M, Martín DH, Woytinek K, Schmidt B, Tabari D, Scholl C, et al. Targeting cholesterol metabolism as efficient antiviral strategy against the hepatitis E virus. Cell MolGastroenterol Hepatol. 2021;12(1):159–80. https://doi.org/10.1016/j.jcmgh.2021.02.002.CrossRef

14.

Zhang Y, Wang Z, Chen H, Chen Z, Tian Y. Antioxidants: potential antiviral agents for Japanese encephalitis virus infection. IntJ InfectDis. 2014;24:30–6. https://doi.org/10.1016/j.ijid.2014.02.011.CrossRef

15.

Tao L, Lowe A, Wang G, Dozmorov I, Chang T, Yan N, Reese TA. Metabolic control of viral infection through PPAR-α regulation of STING signaling. BioRxiv. 2019;13:17.

16.

Sychev ZE, Hu A, DiMaio TA, Gitter A, Camp ND, Noble WS, et al. Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLOSPathog. 2017;13(3): e1006256. https://doi.org/10.1371/journal.ppat.1006256.CrossRef

17.

Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma. 2007;24(7):1119–31. https://doi.org/10.1089/neu.2006.0216.CrossRefPubMed

18.

Undas A, Celinska-Löwenhoff M, Domagala TB, Iwaniec T, Dropinski J, Löwenhoff T, Szczeklik A. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005;94(1):193–9. https://doi.org/10.1160/TH05-01-0067.CrossRefPubMed

19.

Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity. 2009;17(3):504–9. https://doi.org/10.1038/oby.2008.530.CrossRefPubMed

20.

Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J BiolChem. 2000;275(47):36703–7. https://doi.org/10.1074/jbc.M004045200.CrossRef

21.

Chen N, Jiang K, Yan GG. Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(19):8630–6. https://doi.org/10.26355/eurrev_201910_19180.CrossRefPubMed

22.

Koh KK, Han SH, Quon MJ, Yeal Ahn JY, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28(6):1419–24. https://doi.org/10.2337/diacare.28.6.1419.CrossRefPubMed

23.

Rada MJ, Donato M, Penas FN, Alba Soto CD, Cevey ÁC, Pieralisi AV, et al. IL-10-dependent and-independent mechanisms are involved in the cardiac pathology modulation mediated by fenofibrate in an experimental model of Chagas heart disease. Front Immunol. 2020;11:2429.CrossRef

24.

Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, et al. Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10–deficient mice. Gastroenterology. 2007;133(1):108–23. https://doi.org/10.1053/j.gastro.2007.03.113.CrossRefPubMed

25.

Wahba MG, Messiha BA, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. PharmBiol. 2016;54(9):1705–15. https://doi.org/10.3109/13880209.2015.1125931.CrossRef

26.

Shirinsky IV, Shirinsky VS. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. RheumatolInt. 2014;34(5):613–6. https://doi.org/10.1007/s00296-013-2766-4.CrossRef

27.

Chistyakov DV, Astakhova AA, Goriainov SV, Sergeeva MG. Comparison of PPAR ligands as modulators of resolution of inflammation, via their influence on cytokines and oxylipins release in astrocytes. IntJ MolSci. 2020;21(24):9577. https://doi.org/10.3390/ijms21249577.CrossRef

28.

Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Alexiou A, Batiha GE. Niclosamide for Covid-19: bridging the gap. MolBiolRep. 2021;48(12):8195–202. https://doi.org/10.1007/s11033-021-06770-7.CrossRef

29.

Onohuean H, Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Batiha GE. Covid-19 and development of heart failure: mystery and truth. Naunyn-SchmiedebergsArch Pharmacol. 2021;394(10):2013–21. https://doi.org/10.1007/s00210-021-02147-6.CrossRef

30.

Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Alexiou A, Batiha GE. Levamisole therapy in COVID-19. Viral Immunol. 2021;34(10):722–5. https://doi.org/10.1089/vim.2021.0042.CrossRefPubMed

31.

Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Gyebi GA, Batiha GE. Covid-19-induced dysautonomia: a menace of sympathetic storm. ASN Neuro. 2021;13:17590914211057636. https://doi.org/10.1177/17590914211057635.CrossRefPubMedPubMedCentral

32.

Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Cruz-Martins N, El-Saber Batiha GE. Sequential doxycycline and colchicine combination therapy in Covid-19: the salutary effects. PulmPharmacol Ther. 2021;67: 102008. https://doi.org/10.1016/j.pupt.2021.102008.CrossRef

33.

Al-Kuraishy HM, Al-Gareeb AI, Alqarni M, Cruz-Martins N, El-Saber BG. Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Front Pharmacol. 2021;12: 642822. https://doi.org/10.3389/fphar.2021.642822.CrossRefPubMedPubMedCentral

34.

Batiha GE. Cyclosporine attenuates Covid-19: ensnare or victory. Ann Clin Med Case Rep. 2021;7(4):1–8.

35.

Hassan T. Fenofibrate, a drug for COVID-19? All we need to know. J Rawalpindi Med Coll. 2021;25(4):441–2.

36.

Gupta RK, Nwachuku EL, Zusman BE, Jha RM, Puccio AM. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLOSONE. 2021;16(9): e0257784. https://doi.org/10.1371/journal.pone.0257784.CrossRef

37.

Yasmin F, Zeeshan MH, Ullah I. The role of fenofibrate in the treatment of COVID-19. Ann Med Surg. 2022;74: 102974. https://doi.org/10.1016/j.amsu.2021.102974.CrossRef

38.

Buschard K. Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. MedHypotheses. 2020;143: 110127. https://doi.org/10.1016/j.mehy.2020.110127.CrossRef

39.

Guo R, Hu X, Yamada Y, Harada M, Nakajima T, Kashihara T, et al. Effects of hypertension and antihypertensive treatments on sulfatide levels in serum and its metabolism. HypertensRes. 2019;42(5):598–609. https://doi.org/10.1038/s41440-018-0160-z.CrossRef

40.

Blomqvist M, Kaas A, Månsson JE, Formby B, Rynmark BM, Buschard K, Fredman P. Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosylceramide in mammalian pancreas. J Cell Biochem. 2003;89(2):301–10. https://doi.org/10.1002/jcb.10513.CrossRefPubMed

41.

Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008;100(4):530–47. https://doi.org/10.1160/TH08-03-0147.CrossRefPubMed

42.

Novakova L, Singh AK, Axelsson M, Ståhlman M, Adiels M, Malmeström C, et al. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS. J Neurochem. 2018;146(3):322–32. https://doi.org/10.1111/jnc.14452.CrossRefPubMed

43.

Takahashi T, Murakami K, Nagakura M, Kishita H, Watanabe S, Honke K, et al. Sulfatide is required for efficient replication of influenza A virus. J Virol. 2008;82(12):5940–50. https://doi.org/10.1128/JVI.02496-07.CrossRefPubMedPubMedCentral

44.

Takahashi T, Suzuki T. Role of sulfatide in virus infection and replication. Trends Glycosci Glycotechnol. 2009;21(121):255–65. https://doi.org/10.4052/tigg.21.255.CrossRef

45.

Ehrlich A, Uhl S, Ioannidis K, Hofree M, tenOever BR, Nahmias Y. The SARS-CoV-2 transcriptional metabolic signature in lung epithelium. SSRN Electron J. 2020. https://doi.org/10.2139/ssrn.3650499.CrossRef

46.

Pawar A, PalA GK, Squitti R, Rongiolettie M. Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. Results Chem. 2021;3:100148. https://doi.org/10.1016/j.rechem.2021.100148.CrossRefPubMedPubMedCentral

47.

Cui H, Xie N, Banerjee S, Ge J, Guo S, Liu G. Impairment of fatty acid oxidation in alveolar epithelial cells mediates acute lung injury. AmJ RespirCell MolBiol. 2019;60(2):167–78. https://doi.org/10.1165/rcmb.2018-0152OC.CrossRef

48.

Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, et al. Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury. EurRespirJ. 2008;32(5):1344–53. https://doi.org/10.1183/09031936.00035808.CrossRef

49.

Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N, Pons F. PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse. RespirRes. 2005;6(1):91. https://doi.org/10.1186/1465-9921-6-91.CrossRef

50.

Shao Y, Chen J, Dong LJ, He X, Cheng R, Zhou K, et al. A protective effect of PPARα in endothelial progenitor cells through regulating metabolism. Diabetes. 2019;68(11):2131–42. https://doi.org/10.2337/db18-1278.CrossRefPubMedPubMedCentral

51.

Heffernan KS, Ranadive SM, Jae SY. Exercise as medicine for COVID-19: on PPAR with emerging pharmacotherapy. MedHypotheses. 2020;143: 110197. https://doi.org/10.1016/j.mehy.2020.110197.CrossRef

52.

Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? EurRespirJ. 2020;56(1):2001634. https://doi.org/10.1183/13993003.01634-2020.CrossRef

53.

Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. NatRevImmunol. 2021;21(5):319–29. https://doi.org/10.1038/s41577-021-00536-9.CrossRef

54.

BrandãoSCS RamosJOX, Dompieri LT, GodoiETAM FJL, SarinhoESC, et al. Is toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? CytokineGrowth Factor Rev. 2021;58:102–10. https://doi.org/10.1016/j.cytogfr.2020.09.002.CrossRef

55.

Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor γ and nuclear factor-κB in macrophages. Immunology. 2008;125(3):344–58. https://doi.org/10.1111/j.1365-2567.2008.02849.x.CrossRefPubMedPubMedCentral

56.

Tutunchi H, Saghafi-Asl M, Ostadrahimi A. A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity. Clin ExpPharmacol Physiol. 2020;47(4):543–52. https://doi.org/10.1111/1440-1681.13238.CrossRef

57.

Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. https://doi.org/10.3389/fimmu.2020.01708.CrossRefPubMedPubMedCentral

58.

Ji Y, Wang Z, Li Z, Liu J. Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2010;25(6):631–40. https://doi.org/10.1159/000315082.CrossRefPubMed

59.

Garcia-Ramírez M, Hernández C, Palomer X, Vázquez-Carrera M, Simó R. Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity. Acta diabetol. 2016;53(1):109–18. https://doi.org/10.1007/s00592-015-0759-3.CrossRefPubMed

60.

Jiang Q, Wang S, Shi Y. Posttreatment with LYRM03 protects rats from acute lung inflammation induced by lipopolysaccharide via suppressing the NF-κB/MyD88/TLR4 axis. J SurgRes. 2019;243:316–24. https://doi.org/10.1016/j.jss.2019.05.036.CrossRef

61.

Zhu Q, He G, Wang J, Wang Y, Chen W. Protective effects of fenofibrate against acute lung injury induced by intestinal ischemia/reperfusion in mice. SciRep. 2016;6(1):22044. https://doi.org/10.1038/srep22044.CrossRef

62.

Batiha GE, Al-GareebDAI QS, Alshammari EM, Rotimi D, Adeyemi OS, Al-Kuraishy HM. Common NLRP3 inflammasome inhibitors and Covid-19: divide and Conquer. SciAfr. 2021. https://doi.org/10.1016/j.sciaf.2021.e01084.CrossRef

63.

Liu Q, Zhang F, Zhang X, Cheng R, Ma JX, Yi J, Li J. Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. Mol Cell Biochem. 2018;445(1–2):105–15. https://doi.org/10.1007/s11010-017-3256-x.CrossRefPubMed

64.

Zhu DD, Tan XM, Lu LQ, Yu SJ, Jian RL, Liang XF, et al. Interplay between nuclear factor erythroid 2-related factor 2 and inflammatory mediators in COVID-19-related liver injury. World J Gastroenterol. 2021;27(22):2944–62. https://doi.org/10.3748/wjg.v27.i22.2944.CrossRefPubMedPubMedCentral

65.

Grimes JM, Grimes KV. p38MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol. 2020;144:63–5. https://doi.org/10.1016/j.yjmcc.2020.05.007.CrossRefPubMedPubMedCentral

66.

Hou X, Shen YH, Li C, Wang F, Zhang C, Bu P, Zhang Y. PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem BiophysResCommun. 2010;394(3):653–9. https://doi.org/10.1016/j.bbrc.2010.03.043.CrossRef

67.

Cheng SM, Chu KM, Lai JH. The modulatory mechanisms of fenofibrate on human primary T cells. EurJ PharmSci. 2010;40(4):316–24. https://doi.org/10.1016/j.ejps.2010.04.003.CrossRef

68.

Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. J MedVirol. 2020;92(9):1495–500. https://doi.org/10.1002/jmv.26009.CrossRef

69.

Terrazzano G, Rubino V, Palatucci AT, Giovazzino A, Carriero F, Ruggiero G. An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy? Front Pharmacol. 2020;11:856. https://doi.org/10.3389/fphar.2020.00856.CrossRefPubMedPubMedCentral

70.

Lian X, Gu J, Gao B, Li Y, Damodaran C, Wei W, et al. Fenofibrate inhibits mTOR-p70s6K signaling and simultaneously induces cell death in human prostate cancer cells. Biochem BiophysResCommun. 2018;496(1):70–5. https://doi.org/10.1016/j.bbrc.2017.12.168.CrossRef

71.

Yalcin Kehribar D, Cihangiroglu M, Sehmen E, Avci B, Capraz A, Yildirim Bilgin A, et al. The receptor for advanced glycation end product (RAGE) pathway in COVID-19. Biomarkers. 2021;26(2):114–8. https://doi.org/10.1080/1354750X.2020.1861099.CrossRefPubMed

72.

Lim A, Radujkovic A, Weigand MA, Merle U. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality. Ann IntensiveCare. 2021;11(1):50. https://doi.org/10.1186/s13613-021-00836-2.CrossRef

73.

Ju HB, Zhang FX, Wang S, Song J, Cui T, Li LF, Zhang HY. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. Medicine. 2017;96(31): e7671. https://doi.org/10.1097/MD.0000000000007671.CrossRefPubMedPubMedCentral

74.

Turkia M. COVID-19 as an endothelial disease and its relationship to vascular endothelial growth factor (VEGF) and iodide. SSRN Electron J. 2020. https://doi.org/10.2139/ssrn.3604987.CrossRef

75.

Jonnalagadda VG, Shaik A. Statin on insulin and adiponectin levels: true or false prophecy? Diabetes Metab Syndr Obes. 2018;11:131. https://doi.org/10.2147/DMSO.S160853.CrossRefPubMedPubMedCentral

76.

Singh P, Zhang Y, Sharma P, Covassin N, Soucek F, Friedman PA, Somers VK. Statins decrease leptin expression in human white adipocytes. PhysiolRep. 2018;6(2): e13566. https://doi.org/10.14814/phy2.13566.CrossRef

77.

Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208. https://doi.org/10.1016/j.atherosclerosis.2016.07.897.CrossRefPubMed

78.

Liu B, Wu R, Zhang W, Zhang F, Zhou H, Wang L, et al. Fosinopril improves liver fibrosis by upregulating ACE2/angiotensin-(1–7) axis activation in rats with nonalcoholic steatohepatitis. LatAmJ Pharm. 2012;31:588–96.

79.

Cheema PS, Nandi D, Nag A. Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19. Open Biol. 2021;11(6): 210069. https://doi.org/10.1098/rsob.210069.CrossRefPubMedPubMedCentral

80.

Newaz M, Blanton A, Fidelis P, Oyekan A. NAD (P) H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) α-mediated cardiovascular effects. Mutat Res. 2005;579(1–2):163–71. https://doi.org/10.1016/j.mrfmmm.2005.02.024.CrossRefPubMed

81.

Esenboga K, Çiçek ÖF, Oktay AA, Ayral PA, Gürlek A. Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia. Adv Clin ExpMed. 2019;28(7):931–6. https://doi.org/10.17219/acem/94161.CrossRef

82.

Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. CurrHypertensRep. 2020;22(9):63. https://doi.org/10.1007/s11906-020-01078-6.CrossRef

83.

Lee JJ, Jin YR, Yu JY, Munkhtsetseg T, Park ES, Lim Y, et al. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis. 2009;206(2):375–82. https://doi.org/10.1016/j.atherosclerosis.2009.02.034.CrossRefPubMed

84.

Kilicarslan A, Yavuz B, Guven GS, Atalar E, Sahiner L, Beyazit Y, et al. Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagul Fibrinolysis. 2008;19(4):310–4. https://doi.org/10.1097/MBC.0b013e3283009c69.CrossRefPubMed

85.

Kashi M, Jacquin A, Dakhil B, Zaimi R, Mahé E, Tella E, Bagan P. Severe arterial thrombosis associated with Covid-19 infection. ThrombRes. 2020;192:75–7. https://doi.org/10.1016/j.thromres.2020.05.025.CrossRef

86.

Feher M, Joy M, Munro N, Hinton W, Williams J, de Lusignan S. Fenofibrate as a COVID-19 modifying drug: laboratory success versus real-world reality. Atherosclerosis. 2021;1(339):55–6.CrossRef

87.

Garg H, Khanna P. Covid and cholesterol (C&C): something to worry about or much ado about nothing? Trends Anaesth Crit Care. 2021;36:39–40.CrossRef

88.

Lee HW, Kang WY, Jung W, Gwon MR, Cho K, Yang DH, Yoon YR, Seong SJ. Evaluation of the pharmacokinetic drug–drug interaction between micronized fenofibrate and pitavastatin in healthy volunteers. Pharmaceutics. 2020;12(9):869.CrossRefPubMedCentral

89.

Pawar A, Pal A, Goswami K, Squitti R, Rongiolettie M. Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. Results Chem. 2021;1(3): 100148.CrossRef

Titel: Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail
verfasst von: Shadi Salem Alkhayyat
Hayder M. Al-kuraishy
Ali I. Al-Gareeb
Maisra M. El-Bouseary
Amal M. AboKamer
Gaber El-Saber Batiha
Jesus Simal-Gandara
Publikationsdatum: 08.08.2022
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Inflammation Research / Ausgabe 10-11/2022
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-022-01615-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10-11/2022

The HMGB1-RAGE axis induces apoptosis in acute respiratory distress syndrome through PERK/eIF2α/ATF4-mediated endoplasmic reticulum stress

Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction

IL-25 directly modulates adipocyte function and inflammation through the regulation of adiponectin

Lipoxin alleviates oxidative stress: a state-of-the-art review

Increased miR-124-3p alleviates type 2 inflammatory response in allergic rhinitis via IL-4Rα

Synergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis